Thrombocytosis Clinical Trial
Official title:
The Role of Reactive Thrombocytosis in Children With Pneumococcal Infection
| NCT number | NCT01194349 |
| Other study ID # | WFH-PED 001, Version 2.990526 |
| Secondary ID | |
| Status | Completed |
| Phase | N/A |
| First received | August 31, 2010 |
| Last updated | September 1, 2010 |
| Verified date | May 2010 |
| Source | Taipei Medical University WanFang Hospital |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Taiwan: Department of Health |
| Study type | Observational |
Thrombocytosis, mostly reactive in nature, is common in pediatric hospitalized patients with infections. Streptococcus pneumoniae (S. Pneumoniae) is the most common pathogen. In this study, the investigators investigated the associations of clinical profiles and thrombocytosis and evaluated platelet counts, leukocyte counts and CRP levels as predictors of hospitalization days in patients with S. pneumoniae infection.
| Status | Completed |
| Enrollment | 0 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 1 Year to 18 Years |
| Eligibility |
Inclusion Criteria: - Pediatric patients diagnosed with pneumococcal infection. Exclusion Criteria: - Patients with automatic discharge. |
Observational Model: Case-Only, Time Perspective: Retrospective
| Country | Name | City | State |
|---|---|---|---|
| Taiwan | Jinn-Li Wang | Taipei |
| Lead Sponsor | Collaborator |
|---|---|
| Taipei Medical University WanFang Hospital | University of Alberta |
Taiwan,
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02308787 -
Retrospective Data Collection of Routine Use With Spectra Optia® for Platelet Depletions
|
N/A | |
| Completed |
NCT01787552 -
A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF
|
Phase 1/Phase 2 | |
| Completed |
NCT02125318 -
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
|
Phase 2 | |
| Completed |
NCT00509899 -
Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
|
Phase 1/Phase 2 | |
| Recruiting |
NCT00722527 -
Molecular Biology of Polycythemia and Thrombocytosis
|
||
| Terminated |
NCT00882414 -
Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)
|
Phase 2 | |
| Recruiting |
NCT03531515 -
Predictors of Reactive Thrombocytosis in Critically Ill Septic Patients
|